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Inborn Error of Metabolism is a Disease of any Age; Carniting
Palmitoyltransferase II Deficiency and Its Manifestations
Mira Mitry, MD, James Ross MD, FACP
Lehigh Valley Health Network, Allentown, Pennsylvania
Introduction:
• C
 arnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fattyacid oxidation. The three clinical presentations are: lethal neonatal form, severe infantile
hepatocardiomuscular form, and myopathic form.

Chief Complaint: “Pain in my thighs”.
Case:
• 3 0 years old female with PMH of migraine and seizures, presented with severe pain in
her thighs. According to the patient, she went to the gym 2 days prior to admission, to
do her usual workout, which consists of an hour of running or aerobic exercise. However,
a personal trainer offered her a tense 15-minutes workout that consisted of significant
amount of squats.
• L ater that day, she noticed tightness, and muscle stiffness in her thighs, which became
progressively worse to the point she could not stand or walk. She also noticed that her
urine was getting dark red/black in color.
Going Back Into Her History:
• P er patient, she would awake every morning as a child with numbness in her legs, which
would resolve eventually with standing. By the time she was 17, she began having
episodes associated with muscle pain, weakness, and fatigue with exercise. If her
muscles’ pain is severe enough, she would develop a seizure like activity, followed by a
transient loss of consciousness. There is no postictal state.
• L ess severe more frequent pain during her daily activity without definite exercise.
Past Medical History: Questionable seizures; her EEG was abnormal but nonspecific.
Migraine, polycystic ovarian disease and fibromyalgia.
Medications: Topamax, Aldactone, OCP.
Family History: Brother has myalgia and darkening of urine after exercise but it was
never worked up. Sister had 2 episodes of passing out, but no workup was done. Cousin with
epilepsy.
Vitals: Temp = 97.9, HR = 85, Bp = 117/74, RR = 20, and SpO2 = 93% on RA.
General: AAOx3, no apparent distress.

Carnitine Palmitoyltransferase II:

• C
 arnitine palmitoyl transferase II  (CPT II), is an enzyme located in the inner aspect of the inner
mitochondrial membrane, that cleaves the long chain acylcarnitine complex. Subsequently, long chain
fatty acid could be used in beta oxidation, and production of energy in the liver, cardiac muscle and
skeletal muscle.
• D
 uring periods of fasting, or prolong exercise; if fatty acid oxidation is defective, fat can’t be utilized, and
glucose is consumed without regeneration via gluconeogenesis. Eventually hypoglycemia occurs leading
to brain function impairment, seizures and loss of consciousness.
• M
 oreover, fat will accumulate in the liver causing steatosis, heart causing cardiomyopathy and
arrhythmias, and skeletal muscle causing myopathy.  

Carnitine Palmitoyltransferase II Deficiency:

• It has an autosomal recessive pattern of inheritance.
• A majority of affected individuals are homozygous or compound heterozygotes for mutations in the CPT
II gene.
• T he two most common gene defects, S113L and R503C may cause disease in heterozygotes.
• T he three clinical presentations are: lethal neonatal form, severe infantile hepatocardiomuscular form,
and myopathic form. The former 2 presentations are fatal at young age.

The Myopathic Form of CPT II:

Figure 2. CPT II Deficiency.The carnitine cycle in fatty acid oxidation.
In: Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine
transport and the carnitine cycle. American Journal Of Medical Genetics.
Part C, Seminars In Medical Genetics. May 15, 2006;142C(2):77-85.

• T he myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle, and the most frequent cause of hereditary
myoglobinuria.
• S igns/Symptoms
		
		
		

–	Usually noted during first or second decade of life, but can appear as late as the fifth decade.
–	Characterized by attacks of myalgia, muscle stiffness or tenderness, weakness, and fatigue, with or without myoglobinuria. Lethargy and seizures can happen.  
–	When rhabdomyolysis occurs, it may lead to acute renal failure, electrolytes abnormality causing cardiac arrhythmias, and respiratory insufficiency requiring mechanical
ventilation.

• T riggers:
		
		
		

–	Prolonged exercise
–	Cold exposure
–	Fever

		
		

–	Stress or infection
–	Medications that may lower carnitine levels, like pentobarbital, phenytoin, carbamazepine, depakote, sulfadiazine, pyrimethamine,
cefditoren, ipecac, and zidovudine.

• D
 iagnosis
		
		

–	Determination of free and acylcarnitine levels in serum, urine and/tissues.
–	Confirmation by direct enzymatic assay or DNA analysis.

• T reatments; no specific treatment exists. Preventive measures include;

Physical Examination: Physical examin is pertinent for; bilateral lower extremities
were extremely painful and tender on palpation. Tense bilateral thighs and quadriceps. Pain
on pasive motion with rigidity of b/l knees. Sensory exam was intact to pinprick throughout
with subjective decrease in the left medial calf region. The rest of the physican exam was
negative.

		

Labs and Imaging: CBC, Hgb of 14.9, Hematocrit 44.8, WBC 14 and platelets 311. BMP
was within normal range. Ca 9.1, AST 1529, ALT 452, CK is 108,864. Acetaminophen is <10.
UA was positive for blood, but rare RBC on HPF, moblobin test was positive. EKG - normal
sinus rhythm.

Teaching Point:

Hospital Course: Patient was started on aggressive fluid resuscitation for
rhabdomyolysis. Orthopedics were consulted for possible compartment syndrome. Thighs’
anterior compartment pressure was measured, and it was found to be 55-60 on the right
and 90 on the left. Patient was taken for stat fasciotomy.  During which, all her muscles
appeared healthy, clean, viable and contractile.  Also Rheumatology was consulted and
recommendation was to do muscle biopsy during fasciotomy. Muscle biopsy was done
on closure of the fasciotomy and was sent for pathology. Pathology reading, necrotizing
myopathy with excessive lipis storage.
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Diagnosis: Deficiency of Carnitine palmitoyltransferase II.

Figure 1. The Mitochondrial Carnitine System. Linus Palding Institute at
Oregon State University. http://lpi.oregonstate.edu/infocenter/othernuts/
carnitine/transport.html. Accessed April 24, 2014.

		
		
		

–	Diet modification; high carbohydrate, low (medium-chain) fat and low protien diet. Frequent meals. Extra carbohydrate intake before sustained exercise appears to improve
exercise intolerance.
–	Triheptanoin diet appears promising. Larger studies are needed to confirm.
–	Refrain from prolonged aerobic exercise, fasting and cold exposure.
–	Pharmacologic treatment with bezafibrate may be beneficial for mild CPT II deficiency. Larger studies are needed to confirm.

• Internists need to be aware of the manifestations of inborn error of muscle metabolism which can also present in adults. This case was diagnosed 14 years after her
initial presentation and after been evaluated by 22 specialists.
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